Persistent elevation of serum CA 19-9 with no evidence of malignant disease

Digestive and Liver Disease

Volumn 41, Issue 5, 2009, Pages 357-363

  Ventrucci, M ^a   Pozzato, P ^a   Cipolla, A ^a   Uomo, G ^b  

^a Ospedale di Bentivoglio   (Italy)

^b CARDARELLI HOSPITAL   (Italy)

Author keywords

CA 19 9; Tumour markers

Indexed keywords

CA 19-9 ANTIGEN; TUMOR MARKER;

ABDOMINAL RADIOGRAPHY; ACUTE DIARRHEA; ADULT; AGED; ANTIGEN DETECTION; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; COLON DIVERTICULOSIS; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DYSPEPSIA; ECHOGRAPHY; FEMALE; FOLLOW UP; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL RADIOGRAPHY; HUMAN; LUNG FIBROSIS; MALE; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STOMACH ULCER;

AGED; AGED, 80 AND OVER; BILIARY TRACT NEOPLASMS; CA-19-9 ANTIGEN; FALSE POSITIVE REACTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; REFERENCE VALUES; TUMOR MARKERS, BIOLOGICAL;

EID: 63049131354     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2008.04.002     Document Type: Article

References (46)

1. Lamerz R. Role of tumour markers, cytogenetics. Ann Oncol 10 Suppl. 4 (1999) 145-149
2. Okusaka T., Yamada T., and Maekawa M. Serum tumor markers for pancreatic cancer: the dawn of new era?. J Pancreas 7 (2006) 332-336
3. Niederau C., and Grendell J.H. Diagnosis of pancreatic carcinoma. Imaging techniques and tumor markers. Pancreas 7 (1992) 66-86
4. Qin X.L., Wang Z.R., Shi J.S., Lu M., Wang L., and He Q.R. Utility of serum CA 19-9 in diagnosis of cholangiocarcinoma in comparison with CEA. Word J Gastroenterol 10 (2004) 427-432
5. Duraker N., Hot S., Polat Y., Hobek A., Gencler N., and Urhan N. CEA, CA 19-9, and CA125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice. J Surg Oncol 95 (2007) 142-147
6. Cwik G., Wallner G., Skoczylas T., Ciechanski A., and Zinkiewicz K. Cancer antigens 19-9 and 125 in the differential diagnosis of pancreatic mass lesions. Arch Surg 141 (2006) 968-973
7. Reiter W., Stieber P., Reuter C., Nagel D., Lau-Werner U., and Lamerz R. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer. Anticancer Res 20 (2000) 5195-5198
8. Bombski G., Gasiorowska A., Orszulak-Michalak D., Neneman B., Kotynia J., Strzelczyk J., et al. Differences in plasma gastrin, CEA, and CA 19-9 concentration in patients with proximal and distal colorectal cancer. Int J Gastrointest Cancer 31 (2002) 155-163
9. Pectasides D., Mylonakis A., Kostopoulou M., Papadopoulou M., Triantafillis D., Varthalitis J., et al. CEA, CA 19-9, and CA-50 in monitoring gastric carcinoma. Am J Clin Oncol 20 (1997) 348-353
10. Gadducci A., Cosio S., Carpi A., Nicolini A., and Genazzani A.R. Serum tumour markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother 58 (2004) 24-38
11. Basso D., Meggiato T., Fabris C., Plebani M., Fogar P., Panozzo M.P., et al. Extra-hepatic cholestasis determines a reversible increase of glycoproteic tumour markers in benign and malignant diseases. Eur J Clin Invest 22 (1992) 800-804
12. Giannini E., Borro P., Botta F., Chiarbonello B., Fasoli A., Malfatti F., et al. Cholestasis is the main determinant of abnormal CA 19-9 levels in patients with liver cirrhosis. Int J Biol Markers 15 (2000) 226-230
13. Maestranzi S., Przemioslo R., Mitchell H., and Sherwood R.A. The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA. Ann Clin Biochem 35 (1998) 99-103
14. Halme L., Karkkainen P., Isoniemi H., Makisalo H., von Bogulawski K., and Hockerstedt K. Carbohydrate 19-9 antigen as a marker of non-malignant hepatocytic ductular transformation in patients with acute liver failure. A comparison with alpha-fetoprotein and carcinoembryonic antigen. Scand J Gastroenterol 34 (1999) 426-431
15. Schoniger-Hekele M., and Muller C. The combined elevation of tumor markers CA 19-9 and CA 125 in liver disease patients is highly specific for severe liver fibrosis. Dig Dis Sci 51 (2006) 338-345
16. de Goede E., and Yap S.H. An exceptional high concentration of serum CA 19.9 in a patient with alcoholic liver disease. Gut 41 (1997) 579-580
17. Augarten A., Berman H., Aviram M., Diver-Habber A., Akons H., Ben Tur L., et al. Serum CA 19-9 levels as a diagnostic marker in cystic fibrosis patients with borderline sweat tests. Clin Exp Med 3 (2003) 119-123
18. Pines E., Slama J.L., Holeman A., Ley G., Malbec D., and Boudon P. Unusually high CA19-9 in chronic pancreatitis. Gastroenterol Clin Biol 19 (1995) 641-642
19. Mujica V.R., Barkin J.S., and Go V.L. Acute pancreatitis secondary to pancreatic carcinoma. Study Group participants. Pancreas 21 (2000) 329-332
20. Petit J.M., Vaillant G., Olsson N.O., Guignier F., Collignon S., Verges B., et al. Elevated serum CA19-9 levels in poorly controlled diabetic patients. Relationship with Lewis blood group. Gastroenterol Clin Biol 18 (1994) 17-20
21. Mukae H., Hirota M., Kohno S., Komori K., Fukushima K., Hiratani K., et al. Elevation of tumor-associated carbohydrate antigens in patients with diffuse panbronchiolitis. Am Rev Respir Dis 148 (1993) 744-751
22. Totani Y., Saito Y., Miyachi H., Yoneda Y., Shimizu H., Hoshino T., et al. Clinical characterization of CA 19-9 in patients with interstitial pneumonia showing pathological nonspecific interstitial pneumonia pattern. Nihon Kokyuki Gakkai Zasshi 43 (2005) 77-83
23. Cantagrel A., Moulinier L., Beljio K., Duffaut M., Laroche M., Bon E., et al. Increase of CA 19.9 in dysimmune inflammatory rheumatism. Apropos of 6 cases. Rev Rhum Ed Fr 61 (1994) 599-606
24. Harada T., Kubota T., and Aso T. Usefulness of CA19-9 versus CA125 for the diagnosis of endometriosis. Fertil Steril 78 (2002) 733-739
25. Inayama Y., Uesato M., Takase K., Motono N., Nakatani Y., and Kitamura H. Immunohistochemical study of CA 19-9 and SPan-1 in cases of hydronephrosis. Urol Int 57 (1996) 93-98
26. Matsubayashi H., Kuraoka K., Kobayashi Y., Yokota T., Iiri Y., Shichijo K., et al. Ruptured epidermoid cyst and haematoma of spleen: a diagnostic clue of high levels of serum carcinoembryonic antigen, carbohydrate antigen 19-9 and Sialyl Lewis x. Dig Liver Dis 33 (2001) 595-599
27. Ott K., Sendler A., Heidecke C.D., Becker K., Stein H.J., and Siewert J.R. Bronchogenic cyst of the esophagus with high tumor marker levels-a case report and review of the literature. Dis Esophagus 11 (1998) 130-133
28. Vandemergel X., Vandergheynst F., and Decaux G. Very high elevation of CA19-9 level in a patient with steatosis. Acta Gastroenterol Belg 68 (2005) 380-381
29. Nakamura T., Maruyama K., Kashiwabara H., Sunayama K., Ohata K., Fukazawa A., et al. Diverticulitis causing a high serum level of carbohydrate antigen 19-9: report of a case. Surg Today 32 (2002) 282-284
30. Tekin O. Hypothyroidism-related CA 19-9 elevation. Mayo Clin Proc 77 (2002) 398
31. Howaizi M., Abboura M., Krespine C., Sbai-Idrissi M.S., Marty O., and Djabbari-Sobhani M. A new cause for CA19-9 elevation: heavy tea consumption. Gut 52 (2003) 913-914
32. Stern P., Friedecky B., Bartos V., Bezdickova D., Vavrova J., Uhrova J., et al. Comparison of different immunoassays for CA19-9. Clin Chem Lab Med 39 (2001) 1278-1282
33. Ventrucci M., Ubalducci G.M., Cipolla A., Panella M.A., and Ligabue A. Serum CA 242: the search for a valid marker of pancreatic cancer. Clin Chem Lab Med 36 (1998) 179-184
34. Passerini R., Raggio D., Salvatici M., Zorzino L., Radice D., and Sandri M.T. Interchangeability of measurements of CA 19-9 in serum with four frequently used assays: an update. Clin Chem Lab Med 45 (2007) 100-104
35. Witt H. Chronic pancreatitis and cystic fibrosis. Gut 52 Suppl. II (2003) ii31-ii41
36. Ventrucci M., Cipolla A., Racchini C., Casadei R., Simoni P., and Gullo L. Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer. Dig Dis Sci 49 (2004) 1149-1155
37. Tolliver B.A., and O'Brien B.L. Elevated tumor-associated antigen CA 19-9 in a patient with an enlarged pancreas: does it always imply malignancy?. South Med J 90 (1997) 89-90
38. Kim H.J., Kim M.H., Myung S.J., Lim B.C., Park E.T., Yoo K.S., et al. A new strategy for the application of CA 19-9 in the differentiation of pancreaticobiliary cancer: analysis using receiver operating characteristic curve. Am J Gastroenterol 94 (1999) 1941-1946
39. Murohisa T., Sugaya H., Tetsuka I., Suzuki T., and Harada T. A case of common bile duct stone with cholangitis presenting an extraordinary high serum CA 19-9 value. Intern Med 31 (1992) 516-520
40. Mann D.V., Edwards R., Ho S., Lau W.J., and Glazer G. Elevated tumour marker CA19.9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol 26 (2000) 474-479
41. Ohshio G., Manabe T., Watanabe Y., Endo K., Kudo H., Suzuki T., et al. Comparative studies of DU-PAN-2, carcinoembryonic antigen, and CA 19-9 in the serum and bile of patients with pancreatic and biliary tract diseases: evaluation of the influence of obstructive jaundice. Am J Gastroenterol 85 (1990) 1370-1376
42. Dorizzi R.M., Di Leo A., Guglielmi A., and de Manzoni G. Measurement of serum CA 19-9 in biliary diseases requires great caution. Acta Oncologica 40 (2001) 877-878
43. von Ritter C., Eder M.I., Stieber P., Lamerz R., Jungst D., Strigl M., et al. Biliary mucin secreted by cultured human gallbladder epithelial cells carries the epitope of CA 19-9. Anticancer Res 17 (1997) 2931-2934
44. Madonia S., Aragona E., Maisano S., Montalbano L., Olivo M., Rossi F., et al. CA 19-9 to rule out pancreatic or biliary cancer among patients with cholestasis: an unsuitable test?. Dig Dis Sci 52 (2007) 1125-1127
45. Lachmann H.J., and Hawkins P.N. Systemic amyloidosis. Curr Opin Pharmacol 6 (2006) 214-220
46. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313-27.